Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma

Blood

Volumn 89, Issue 11, 1997, Pages 3974-3979

  Zinzani, Pier Luigi ^a   Pavone, Enzo ^b   Storti, Sergio ^b   Moretti, Luciano ^b   Fattori, Pier Paolo ^b   Guardigni, Luciano ^b   Falini, Brunangelo ^b   Gobbi, Marco ^b   Gentilini, Patrizia ^b   Lauta, Vito Michele ^b   Bendandi, Maurizio ^b   Gherlinzoni, Filippo ^b   Magagnoli, Massimo ^b   Venturi, Stefamia ^b   Aitini, Enrico ^b   Tabanelli, Maurizio ^b   Leone, Giuseppe ^b   Liso, Vincenzo ^b   Tura, Sante ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT PLANNING;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MITOXANTRONE; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0030964191     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rabkin CS, Devesa SS, Zahm OS, Gail MH: Increasing incidence of non-Hodgkin's lymphoma. Semin Hematol 30:286, 1993
2. d'Amore F, Brincker H, Christensen BE: Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. Ann Oncol 3:379, 1992
3. Moller Jensen O, Esteve J, Moller H, Renard H: Cancer in the European Community and its member states. Eur J Cancer 12:1156, 1990
4. Armitage JO, Potter JF: Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age. J Am Geriatr Soc 32:269, 1984
5. Begg CB, Carbone PP: Clinical trials and drug toxicity in the elderly: The experience of the Eastern Cooperative Oncology Group. Cancer 52:1086, 1983
6. Sweetenham JW, Williams CJ: Malignant lymphoma in the elderly. Baillieres Clin Hematol 1:493, 1987
7. Repetto L, Vercelli M, Simoni C, Venturino A, Biancardi V, Reggiardo G, D'Onofrio A, Modenesi M, Rosso R: Comorbidity among elderly patients with and without cancer. Blood 84:1625, 1994 (abstr, suppl 1)
8. Fisher RI, Hubbard SM, DeVita VT, Berard CW, Wesley R, Cossman J, Young RC: Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 58:45, 1981
9. Armitage JO, Dick FR, Corder MP, Garneau SC, Platz CE, Slymen DJ: Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Cancer 50:1695, 1982
10. Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M, Moravec DF, Howe D, Dowling MD, Mailliard J, Johnson PS, Pevnick W, Packard WM, Okerbloom J, Thompson RF, Langdon RM, Soori G, Peterson C: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 6:1838, 1988
11. Coiffier B: What treatment for elderly patients with aggressive lymphoma? Ann Oncol 5:873, 1994
12. The International non-Hodgkin's lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993
13. Grogan L, Corbally N, Dervan PA, Byrne A, Carney DN: Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens. Ann Oncol 5:47, 1994
14. O'Connell MJ, Earle JD, Harrington DP, Johnson GJ, Glick JH: Initial chemotherapy doses for elderly patients with malignant lymphoma. J Clin Oncol 4:1418, 1986
15. Sonneveld P, Michiels JJ: Full-dose chemotherapy in elderly patients with non-Hodgkin's lymphoma. A feasibility study using a mitoxantrone-containing regimen. Br J Cancer 62:105, 1990
16. Zinzani PL, Bendandi M, Gherlinzoni F, Mazza P, Salvucci M, Aitini E, Miggiano MC, Gozzetti A, Tura S: VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. Haematologica 78: 378, 1993
17. Tirelli U, Zagonel V, Errante D, Serraino D, Talamini R, De Cicco M, Carbone A, Monfardini S: A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol 10:228, 1992
18. Salvagno L, Contu A, Bianco A: A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Ann Oncol 3: 833, 1992
19. O'Reilly SE, Klimo P, Connors JM: Low-dose ACOP-B and VABE. Weekly chemotherapy for elderly patients with advancedstage diffuse large-cell lymphoma. J Clin Oncol 9:741, 1991
20. O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS: In search of an optimal regimen for elderly tients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 11:2250, 1993
21. Ansell SM: A phase II trial of chemotherapy combination in elderly patients with aggressive lymphoma. Ann Oncol 4:172, 1993
22. Tirelli U, Carbone A, Zagonel V, Veronesi A, Canetta R: Non-Hodgkin's lymphoma in the elderly: Prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol 23:535, 1987
23. Tigaud JD, Demolombe S, Bastion Y, Bryon PA, Coiffier B: Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma. A phase II study. Hematol Oncol 9:225, 1991
24. McMaster ML, Johnson DH, Greer JP, Wolff SN, Hildreth CR, Greco FA, Hainsworth JD: A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 67:1487, 1991
25. Goss PE, Burkes R, Rudinskas L: Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: A preliminary report. Semin Hematol 31:23, 1994
26. Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, Torromeo C, Mandelli F: P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:2362, 1993
27. Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M, Rota Scalabrini D, Salvi F, Secondo V, Todeschini G, Viero P, Volta C, Resegotti L: PVEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 5:895, 1994
28. Zagonel V, Babare R, Merola MC, Talamini R, Lazzarini R, Tirelli U, Carbone A, Monfardini S: Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 5:127, 1994
29. Stansfeld A, Diebold J, Kapanci Y, Kelenyi G, Lennert K, Mioduszewska O, Noel H, Rilke F, Sundstrom C, van Unnik JAM, Wright DH: Updated Kiel classification for lymphoma. Lancet i:292, 1988
30. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112, 1982
31. Carbone PP, Kaplan HS, Musshoff K: Report of the committee on Hodgkin's disease staging classifications. Cancer Res 31:1860, 1971
32. Oken M, Creech R, Tormey D: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649, 1982
33. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596, 1985
34. Hryniuk WM, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281, 1984
35. Conover WJ: Practical Nonparametric Statistics. New York, NY, Wiley, 1980
36. Cox DR: Analysis of Binary Data. London, UK, Meuthen, 1970
37. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
38. Cox DR: Regression models and life tables (with discussion). JR Stat Soc B 34:187, 1972
39. Dixon DO, Neilan B, Jones SE, Jones SE, Lipschtz DA, Miller TP, Grozea PN, Wilson HE: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest oncology group experience. J Clin Oncol 4:295, 1986
40. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP: Comparison of a andard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002, 1993
41. Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D, Wilson EC, Frank GL, Leber BF, Sternbach MS, Foster GA, Skingley P, Levine MN: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386, 1995
42. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530, 1995
43. Pettengel R, Gurney H, Radford JA, Deakin DP, James R, lkinson PM, Kane K, Bentley J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430, 1992
44. Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp J, Thiel E, Huber C, Peschl C, Spann W, Emmerich B, Schadek C, Westerhausen M, Pees HW, Radtke H, Engert A, Terhardt E, Schick H, Binder T, Fuchs R, Hasford J, Brandmaier R, Stern AC, Jones TC, Ehrlich HJ, Stein H, Parwaresch M, Tiemann M, Lennert K: Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82:2329, 1993